epoxypropyl ether

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环氧化物
• 英文名称: epoxypropyl ether
• 英文别名: 2-Methyl-3-(3-methyloxiran-2-yl)oxyoxirane
• 化学式: C₆H₁₀O₃
• 分子量: 130.144
• InChiKey: BPEQDTTUKAJORX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  34.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-羟基黄酮 以65%的产率得到epoxypropyl ether
  参考文献：
  名称：

  Antihypertensive chromonoxypropanolamines

  摘要：

  Chromone衍生物，如6或7-(3-氨基-2-羟基丙氧基)-2-苯基色酮、-3-苯基色酮或-2,3-二苯基色酮，可用作降压剂。

  公开号：

  US04495198A1

文献信息

• [EN] CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO<br/>[FR] CONJUGUÉS COMPRENANT DES GROUPES PEPTIDIQUES ET PROCÉDÉS ASSOCIÉS À CEUX-CI
  申请人：LEGOCHEM BIOSCIENCES INC

  公开号：WO2017089894A1

  公开（公告）日：2017-06-01

  In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

  在某些方面，本发明涉及一种抗体药物偶联物，包括：抗体；连接体；以及至少两个活性剂。在优选的实施例中，连接体包括由多个氨基酸组成的肽序列，其中至少两个活性剂通过共价键与氨基酸的侧链连接。抗体药物偶联物可以包括自焚基团，优选地是两个自焚基团。连接体可以包括O-取代的肟，例如，其中肟的氧原子被取代以与活性剂形成共价键连接；肟的碳原子被取代以与抗体形成共价键连接。
• Aminopropanol derivatives of 1,4:3,6-dianhydro-hexitol nitrates, processes for their preparation and their use as medicaments
  申请人：Heinrich Mack Nachf.

  公开号：EP0319030A1

  公开（公告）日：1989-06-07

  Novel aminopropanol derivatives of 1,4:3,6-dianhydro-hexitol nitrates of the general formula I in which X has the meaning given in the specification, processes for their preparation and their use in preventing and treating cardiovascular diseases, angina pectoris and pulmonary hypertension in mammals.

  该专利描述了一种通式I的1,4:3,6-二脱水己糖硝酸盐的新型氨基丙醇衍生物，其中X的含义在说明书中给出，以及制备它们的过程以及在哺乳动物中预防和治疗心血管疾病、心绞痛和肺动脉高压方面的用途。
• Microbubble formation using ultrasound
  申请人：——

  公开号：US20030032879A1

  公开（公告）日：2003-02-13

  Disclosed herein are agents for enhancing the contrast in a diagnostic ultrasound procedure. These agents comprise colloidal dispersions of the liquid-in-liquid type, i.e., emulsions or microemulsions, in which the dispersed liquid phase has a boiling point at or below the body temperature of the organism to be studied and thus undergoes a phase change from a dispersed liquid to a highly echogenic dispersed gaseous foam or kugelschaum following administration to an organism. The liquid state of the dispersed phase allows one to manufacture extremely stable, pharmaceutically acceptable emulsions with particle sizes typically below 1000 nm. The gaseous state at body temperature yields highly echogenic microbubbles, typically below 10,000 nm in diameter, which are effective as ultrasound contrast agents. Intravenous, intraarterial, oral, intraperitoneal, and intrauterine dosage forms, methods of administration, and imaging techniques are described.

  本文公开了一种增强诊断超声成像对比度的药剂。这些药剂包括液体-液体型胶体分散液，即乳液或微乳液，其中分散液相在被检测生物体的体温以下沸点，因此在给生物体注射后从分散液体相转变为高声学对比度的分散气态泡沫或库格尔沙。分散相的液态使得可以制造粒径通常低于1000纳米的极其稳定的药用乳剂。体温下的气态产生高声学对比度的微泡，直径通常低于10,000纳米，有效作为超声对比剂。描述了静脉、动脉内、口服、腹腔内和子宫内剂量形式、给药方法和成像技术。
• Phase shift colloids as ultrasound contrast agents
  申请人：Quay C. Steven

  公开号：US20050053552A1

  公开（公告）日：2005-03-10

  Agents for enhancing the contrast in a diagnostic ultrasound procedure comprise colloidal dispersions of the liquid-in-liquid type, i.e., emulsions or microemulsions, in which the dispersed liquid phase is a liquid having a boiling point below the temperature of the animal to be imaged and which therefore undergoes a phase change from a dispersed liquid to a highly echogenic dispersed gaseous foam or kugelschaum following administration to the animal. The liquid state of the dispersed phase allows one to manufacture extremely stable, pharmaceutically acceptable emulsions with particle sizes typically below 1000 nm. The gaseous state at body temperature yields highly echogenic microbubbles, typically below 10,000 nm in diameter, which are effective as ultrasound contrast agents. Intravenous, intraarterial, oral, intraperitoneal, and intrauterine dosage forms, methods of administration, and imaging techniques are described.

  用于增强诊断超声程序对比度的药剂包括液-液型胶体分散液，即乳液或微乳液，其中分散液相是一种沸点低于待成像动物温度的液体，因此在向动物注射后会发生相变，从分散液变为高回声分散气体泡沫或库格尔沙姆。分散相的液态使得可以制造非常稳定、药学上可接受的乳液，粒子大小通常小于1000纳米。在体温下的气态产生高回声微气泡，直径通常小于10,000纳米，可以作为超声对比剂有效。描述了静脉、动脉内、口服、腹腔内和子宫内剂量形式、给药方法和成像技术。
• HYBRID EPOXY RESINS
  申请人：DOW GLOBAL TECHNOLOGIES LLC

  公开号：US20140114047A1

  公开（公告）日：2014-04-24

  A hybrid polyfunctional aliphatic and/or cycloaliphatic epoxy (H-PACE) resin composition comprising, consisting of or consisting essentially of: (a) a moiety selected from the group consisting of an aliphatic moiety, a cycloaliphatic moiety, and combinations thereof provided by the polyfunctional aliphatic and/or cycloaliphatic epoxy (PACE) resin; and (b) a moiety selected from the group consisting of an aliphatic moiety, a cycloaliphatic moiety, and combinations thereof, wherein said moiety is not provided by the PACE resin, is disclosed. Processes for making and using such resin composition are also disclosed.

  本发明涉及一种混合多功能脂肪族和/或环脂族环氧（H-PACE）树脂组合物，包括、由以下成分组成或实质上由以下成分组成：（a）由多功能脂肪族和/或环脂族环氧（PACE）树脂提供的脂肪族、环脂族或两者的一部分；以及（b）由不由PACE树脂提供的脂肪族、环脂族或两者的一部分。本发明还公开了制备和使用这种树脂组合物的方法。